Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTX NYSE:QGEN NASDAQ:ROIV NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$13.84-2.8%$14.04$10.60▼$38.12$1.46B0.261.19 million shs301,051 shsQGENQIAGEN$45.36+0.2%$48.47$37.63▼$51.88$10.08B0.641.38 million shs726,758 shsROIVRoivant Sciences$14.10+0.1%$11.86$8.73▼$14.48$9.63B1.155.92 million shs3.24 million shsSRPTSarepta Therapeutics$17.28-0.6%$17.75$10.41▼$138.81$1.68B0.496.33 million shs3.65 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics0.00%-8.54%+0.64%-3.00%-24.38%QGENQIAGEN0.00%-4.70%-8.23%-4.56%+0.51%ROIVRoivant Sciences0.00%+8.98%+18.82%+27.08%+17.92%SRPTSarepta Therapeutics0.00%-7.06%-20.27%-16.95%-86.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$13.84-2.8%$14.04$10.60▼$38.12$1.46B0.261.19 million shs301,051 shsQGENQIAGEN$45.36+0.2%$48.47$37.63▼$51.88$10.08B0.641.38 million shs726,758 shsROIVRoivant Sciences$14.10+0.1%$11.86$8.73▼$14.48$9.63B1.155.92 million shs3.24 million shsSRPTSarepta Therapeutics$17.28-0.6%$17.75$10.41▼$138.81$1.68B0.496.33 million shs3.65 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics0.00%-8.54%+0.64%-3.00%-24.38%QGENQIAGEN0.00%-4.70%-8.23%-4.56%+0.51%ROIVRoivant Sciences0.00%+8.98%+18.82%+27.08%+17.92%SRPTSarepta Therapeutics0.00%-7.06%-20.27%-16.95%-86.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.91Moderate Buy$40.55191.07% UpsideQGENQIAGEN 2.27Hold$49.699.18% UpsideROIVRoivant Sciences 3.50Strong Buy$17.6726.51% UpsideSRPTSarepta Therapeutics 2.07Hold$39.32124.48% UpsideCurrent Analyst Ratings BreakdownLatest EWTX, QGEN, ROIV, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025SRPTSarepta TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.009/9/2025SRPTSarepta TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$12.00 ➝ $15.009/2/2025ROIVRoivant SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight ➝ Buy$16.008/25/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell8/20/2025SRPTSarepta TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$17.008/19/2025EWTXEdgewise TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $30.008/15/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$12.008/8/2025EWTXEdgewise TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$48.00 ➝ $49.008/7/2025QGENQIAGENCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/7/2025QGENQIAGENUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$48.00 ➝ $50.008/7/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$19.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.84 per shareN/AQGENQIAGEN$1.98B5.11$3.22 per share14.13$16.05 per share2.84ROIVRoivant Sciences$29.05M328.28N/AN/A$7.45 per share1.87SRPTSarepta Therapeutics$2.48B0.69$2.45 per share7.14$15.99 per share1.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$133.81M-$1.55N/AN/AN/AN/A-30.65%-29.18%11/6/2025 (Estimated)QGENQIAGEN$83.59M$1.6926.9018.502.3918.30%14.77%8.87%11/5/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A1.60N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)Latest EWTX, QGEN, ROIV, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025EWTXEdgewise Therapeutics-$0.42-$0.34+$0.08-$0.34N/AN/A8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 million8/5/2025Q2 2025QGENQIAGEN$0.60$0.60N/A$0.44$523.97 million$533.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AQGENQIAGEN$0.250.55%N/A14.79%N/AROIVRoivant SciencesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A28.8728.87QGENQIAGEN0.251.611.35ROIVRoivant SciencesN/A40.5440.54SRPTSarepta Therapeutics0.842.891.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/AQGENQIAGEN70.00%ROIVRoivant Sciences64.76%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics23.20%QGENQIAGEN9.00%ROIVRoivant Sciences10.80%SRPTSarepta Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics60105.35 million80.91 millionOptionableQGENQIAGEN5,765222.29 million202.29 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableEWTX, QGEN, ROIV, and SRPT HeadlinesRecent News About These CompaniesInspire Investing LLC Buys New Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 15 at 5:10 AM | marketbeat.comQ3 EPS Forecast for Sarepta Therapeutics Raised by AnalystSeptember 13 at 7:21 AM | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for SRPT EarningsSeptember 12 at 8:43 AM | marketbeat.comLeerink Partnrs Issues Positive Outlook for SRPT EarningsSeptember 12 at 2:39 AM | americanbankingnews.comLeerink Partnrs Analysts Boost Earnings Estimates for SRPTSeptember 12 at 2:03 AM | americanbankingnews.comLeerink Partners Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $15.00September 11, 2025 | marketbeat.comBrokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $43.50September 11, 2025 | americanbankingnews.com15,163 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by Scientech Research LLCSeptember 10, 2025 | marketbeat.comLeerink Partners Issues Positive Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock PriceSeptember 10, 2025 | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by AnalystsSeptember 9, 2025 | marketbeat.comEventide Asset Management LLC Lowers Position in Sarepta Therapeutics, Inc. $SRPTSeptember 6, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Stock Holdings Lifted by EcoR1 Capital LLCSeptember 6, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Shares Up 6.1% - Still a Buy?September 5, 2025 | marketbeat.comSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic YearSeptember 5, 2025 | businesswire.comSarepta Therapeutics, Inc. $SRPT Shares Purchased by 683 Capital Management LLCSeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires 82,919 Shares of Sarepta Therapeutics, Inc. $SRPTSeptember 4, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Shares Sold by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comPDT Partners LLC Raises Stock Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 4, 2025 | marketbeat.comSarepta Therapeutics (SRPT) Fell Despite Reporting Good ResultsSeptember 3, 2025 | finance.yahoo.comSarepta Therapeutics, Inc. $SRPT Shares Sold by Braidwell LPSeptember 3, 2025 | marketbeat.comSarepta Therapeutics Restructures Amid ELEVIDYS ChallengesSeptember 1, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEWTX, QGEN, ROIV, and SRPT Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$13.84 -0.40 (-2.81%) As of 03:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.QIAGEN NYSE:QGEN$45.36 +0.08 (+0.18%) As of 03:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Roivant Sciences NASDAQ:ROIV$14.10 +0.02 (+0.11%) As of 03:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Sarepta Therapeutics NASDAQ:SRPT$17.28 -0.11 (-0.62%) As of 03:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
